Expert Practice<sup>SM</sup> in Chronic Lymphocytic Leukemia
Webcast
Webcast

Expert PracticeSM in Chronic Lymphocytic Leukemia

A Deep Dive Into the Disease

Not a member of My prIME? Join now for instant access.

Strengthen your knowledge of chronic lymphocytic leukemia (CLL) with this in-depth, case-based expert faculty discussion. Initial discussion focuses on details of tumor biology and risk assessment. From there, interactive cases will highlight different patient groups followed by detailed examination of appropriate treatment options. Conventional therapy, new targeted options, and allogeneic stem cell transplantation will be reviewed along with in-depth discussion of the identification and appropriate management of adverse events observed in patients undergoing targeted treatment for CLL. Finally, we look to the future with new treatment options on the horizon.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

May 31, 2017

Expiration Date

May 31, 2018

Getting our feet wet: Understanding the tumor biology and genomic heterogeneity of CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Prognosis and risk assessment in CLL: Are we making progress or just treading water?
Véronique Leblond, MD

Case #1—Diving in: Selecting initial therapy for a fit patient with CLL
Jennifer R. Brown, MD, PhD

Case #2—Charting a course: Critical decisions in the front-line management of elderly patients with CLL
Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Case #3—Making waves: Expanding options for the treatment of relapsed/refractory CLL
Barbara Eichhorst, MD, PhD

Case #4—Turning the tide: Addressing drug resistance in CLL
Anders Österborg, MD, PhD

Shifting sand: The evolving role for allogeneic stem cell transplantation in CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Case #5—Safety is key: Management of adverse events in patients with CLL
Anders Österborg, MD, PhD

Watching the horizon: What can we expect in the coming year?
Barbara Eichhorst, MD, PhD

Chair:

  • John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
    London, United Kingdom

Faculty:

  • Jennifer R. Brown, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Barbara Eichhorst, MD, PhDUniversity Hospital Cologne
    Cologne, Germany
  • Peter Hillmen, MBChB, FRCP, FRCPath, PhDSt James's University Hospital
    Leeds, United Kingdom
  • Véronique Leblond, MDHôpital Pitié Salpêtrière
    Paris, France
  • Anders Österborg, MD, PhDKarolinska University Hospital
    Stockholm, Sweden

This activity is intended for medical oncologists, hematologists, and other healthcare professionals involved in the management of CLL.

After successful completion of this educational activity, participants should be able to:

  • Describe key features of CLL tumor biology and genomic heterogeneity
  • Identify best practices for risk assessment and prognostication for patients with CLL
  • Select optimal therapy for patients with newly diagnosed CLL
  • Distinguish initial treatment options that are appropriate for frail or elderly patients with CLL
  • Incorporate emerging therapies for management of relapsed/refractory CLL
  • Identify patients who are likely to benefit from allogeneic stem cell transplantation
  • Recognize key adverse events associated with available and novel therapies for CLL, as well as strategies to manage toxicity

This program is funded in part via an independent grant from AbbVie.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Brown has disclosed that she received consulting fees from AbbVie, Astellas, AstraZeneca, Celgene, Gilead, Janssen, Novartis, Pfizer, RedX, and Sun BioPharma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Eichhorst has disclosed that she received consulting fees and fees for non-CME services directly from AbbVie, Celgene, Gilead, Janssen, Novartis, and Roche. She also performed contracted research for AbbVie, Gilead, Janssen, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Gribben has disclosed that he received consulting fees from Acerta, Celgene, Cellectis, Gilead, Janssen, Pharmacyclics, Roche/Genentech, TG Therapeutics, and Unum. He also performed contracted research for Acerta and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hillmen has disclosed that he received consulting fees from AbbVie, Celgene, Janssen, Novartis, Pharmacyclics, and Roche. He also performed contracted research for AbbVie, Janssen, Novartis, Pharmacyclics, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Leblond has disclosed that she received consulting fees from AbbVie, Gilead, Janssen, Roche, and Servier. She also received fees for non-CME services directly from AbbVie, Gilead, Janssen, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Österborg has disclosed that he received consulting fees from Janssen. He also performed contracted research for AbbVie and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.